Relevant bibliographies by topics / Glenzocimab

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Conference papers

Academic literature on the topic 'Glenzocimab'

Author: Grafiati
Published: 9 November 2024
Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Glenzocimab.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Glenzocimab"

1

Pottecher, Julien, Francois Raffi, Martine Jandrot-Perrus, et al. "Targeting GPVI with glenzocimab in COVID-19 patients: Results from a randomized clinical trial." PLOS ONE 19, no. 6 (2024): e0302897. http://dx.doi.org/10.1371/journal.pone.0302897.

Full text
Abstract:
Background Glenzocimab is a novel antithrombotic agent which targets platelet glycoprotein VI (GPVI) and does not induce haemorrhage. SARS-CoV-2 triggers a prothrombotic state and lung injury whose mechanisms include coagulopathy, endothelial dysfunction, and inflammation with dysregulated platelets. Methods and patients GARDEN was a randomised double-blind, exploratory phase II study of glenzocimab in SARS-CoV-2 respiratory failure (NCT04659109). PCR+ adults in Brazil and France (7 centres) were randomized to standard-of-care (SOC) plus glenzocimab (1000 mg/dayx3 days) or placebo, followed fo
APA, Harvard, Vancouver, ISO, and other styles
2

Renaud, Lionel, Kristell Lebozec, Christine Voors‐Pette, et al. "Population Pharmacokinetic/Pharmacodynamic Modeling of Glenzocimab (ACT017) a Glycoprotein VI Inhibitor of Collagen‐Induced Platelet Aggregation." Journal of Clinical Pharmacology 60, no. 9 (2020): 1198–208. http://dx.doi.org/10.1002/jcph.1616.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Jandrot-Perrus, M., J. Pottecher, E. Toledano, et al. "PB0364 Glycoprotein VI-Targeted Antiplatelet Therapy with Glenzocimab is Safe in Patients Exposed to Current Antithrombotic and Fibrinolytic Drugs." Research and Practice in Thrombosis and Haemostasis 7 (October 2023): 101499. http://dx.doi.org/10.1016/j.rpth.2023.101499.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Comenducci, Andrea, Adeline Meilhoc, Yannick Pletan, et al. "Abstract 28: Patients Randomised to Glenzocimab Suffered Less Haemorrhagic Transformation at 24 Hours Compared to Placebo: AI-Imaging Sub-Analysis of the ACTIMIS Trial." Stroke 55, Suppl_1 (2024). http://dx.doi.org/10.1161/str.55.suppl_1.28.

Full text
Abstract:
Introduction: ACTIMIS (NCT03803007) was a randomized phase 1b/2a clinical trial evaluating glenzocimab, a monoclonal antibody fragment targeting platelet receptor glycoprotein VI in patients with acute ischemic stroke treated by thrombolysis. Primary analysis demonstrated a reduction in intracranial hemorrhage occurrence stroke-related mortality. In this sub-analysis, volumetric imaging biomarkers were used to assess efficacy of glenzocimab. Methods: In the phase 2a study, patients were randomized (1:1) with 1000mg glenzocimab or placebo. CT or MRI was acquired at baseline with CT at 24 hours
APA, Harvard, Vancouver, ISO, and other styles
5

Comenducci, Andrea, Adeline Meilhoc, Yannick Pletan, et al. "Abstract 006: Glenzocimab Is Associated With Less Haemorrhagic Transformation Using Artificial Intelligence Imaging In Mechanical Thrombectomy Patients." Stroke: Vascular and Interventional Neurology 3, S2 (2023). http://dx.doi.org/10.1161/svin.03.suppl_2.006.

Full text
Abstract:
Introduction Lesion volume measurement provides an objective and quantitative assessment of stroke severity and it is often used as a surrogate endpoint of clinical outcome in therapeutic trials. ACTIMIS (NCT03803007) was a randomized phase 1b/2a clinical trial evaluating glenzocimab, a monoclonal antibody fragment targeting platelet receptor glycoprotein VI, versus placebo in patients with acute ischemic stroke treated by thrombolysis alone or associated with mechanical thrombectomy (MT), both subgroups being well balanced. Primary analysis demonstrated a significant reduction in intracranial
APA, Harvard, Vancouver, ISO, and other styles
6

Wichaiyo, Surasak, Warisara Parichatikanond, and Wipharak Rattanavipanon. "Glenzocimab: A GPVI (Glycoprotein VI)-Targeted Potential Antiplatelet Agent for the Treatment of Acute Ischemic Stroke." Stroke, September 21, 2022. http://dx.doi.org/10.1161/strokeaha.122.039790.

Full text
Abstract:
It has previously been shown in several animal experiments that platelet GPVI (glycoprotein VI) contributes to thrombosis, particularly in ischemic stroke. Moreover, GPVI levels are upregulated in stroke patients. This review describes the therapeutic roles of anti-GPVI antibody in preclinical models of ischemic stroke and provides the current evidence for potential benefits of glenzocimab, a Fab fragment of humanized anti-GPVI monoclonal antibody, in stroke patients. Anti-GPVI antibody, JAQ1, significantly decreased infarct volume and improved neurological function in mice with transient midd
APA, Harvard, Vancouver, ISO, and other styles
7

Alenazy, F. O., M. H. Harbi, D. P. Kavanagh, et al. "GPVI inhibition by glenzocimab synergistically inhibits atherosclerotic plaque-induced platelet activation when combined with conventional dual antiplatelet therapy." European Heart Journal 42, Supplement_1 (2021). http://dx.doi.org/10.1093/eurheartj/ehab724.1425.

Full text
Abstract:
Abstract Introduction Aspirin and a potent platelet P2Y12 inhibitor, such as prasugrel or ticagrelor, are not always sufficient to prevent thrombus formation in patients with ST-elevation MI (STEMI), leading to “slow flow” or “no reflow” effects after stenting. GPIIb/IIIa inhibitors, such as eptifibatide, may help in this setting, but are not used routinely due to their bleeding risk. GPVI has critical roles in thrombosis and a minimal role in haemostasis. Here we tested whether depletion of GPVI has effects on thrombus formation after MI in an animal model and investigated the effects of a no
APA, Harvard, Vancouver, ISO, and other styles
8

Billiald, Philippe, Alexandre Slater, Martin Welin, et al. "Targeting platelet GPVI with glenzocimab: a novel mechanism for inhibition." Blood Advances, November 14, 2022. http://dx.doi.org/10.1182/bloodadvances.2022007863.

Full text
Abstract:
Platelet glycoprotein VI (GPVI) is attracting interest as a potential target for the development of new antiplatelet molecules with a low bleeding risk. GPVI binding to vascular collagen initiates thrombus formation and GPVI interactions with fibrin promote the growth and stability of the thrombus. In the present study we show that glenzocimab, a clinical stage humanized antibody fragment (Fab) with high affinity for GPVI, blocks binding of both ligands through a combination of steric hindrance and structural change. A co-crystal of glenzocimab with an extracellular domain of monomeric GPVI wa
APA, Harvard, Vancouver, ISO, and other styles
9

Dupont, Sébastien, Héloïse Lebas, Sabrina Mavouna, et al. "Comparative Effects of Glenzocimab and Eptifibatide on Bleeding Severity in 2 Mouse Models of Intracranial Hemorrhage." Journal of the American Heart Association, January 17, 2025. https://doi.org/10.1161/jaha.123.034207.

Full text
Abstract:
Background Antiplatelet drugs represent potential candidates for protecting the penumbral microcirculation during cerebral ischemia and improving the benefits of arterial recanalization in ischemic stroke. Yet while the efficacy of such adjuvant strategies has been shown to be highly time dependent, antiplatelet therapy at the acute phase of ischemic stroke cannot be envisioned until the diagnosis of stroke and its ischemic nature have been confirmed because of the presumed risk of worsening bleeding in case of intracranial hemorrhage (ICH). Here, we investigated this risk for 2 antiplatelet d
APA, Harvard, Vancouver, ISO, and other styles
10

Jadoui, Soumaya, Ophélie Le Chapelain, Véronique Ollivier, et al. "Glenzocimab does not impact glycoprotein VI-dependent inflammatory haemostasis." Haematologica, December 30, 2020. http://dx.doi.org/10.3324/haematol.2020.270439.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Glenzocimab"

1

Kern, Axelle Y. "La thrombose de stent : évaluation de l’importance de la rhéologie dans la thrombogénicité des stents et d’un nouvel agent pharmacologique dirigé contre la GPVI pour prévenir la thrombose de stent." Electronic Thesis or Diss., Strasbourg, 2024. http://www.theses.fr/2024STRAJ027.

Full text
Abstract:
Une complication majeure de la pose d’un stent sur une plaque d’athérosclérose est la thrombose de stent, qui présente un taux de mortalité particulièrement élevé. La bithérapie antiplaquettaire, indiquée dans la prévention de cette complication, entraîne un risque important de saignement et n’est pas toujours efficace. L’objectif de ce travail de thèse a consisté à identifier les mécanismes de la thrombose de stent et à évaluer l’intérêt d’une nouvelle classe d'agents antiplaquettaires capables de la prévenir efficacement avec un risque hémorragique faible. Le développement d’un modèle macrof
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Glenzocimab"

1

Pottecher, J., V. A. H. Sato, Y. Plétan, et al. "A Novel Anti-Thrombotic, Glenzocimab, in Covid-19 acute respiratory distress syndrome (Cov-ARDS)." In ERS International Congress 2022 abstracts. European Respiratory Society, 2022. http://dx.doi.org/10.1183/13993003.congress-2022.2878.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Köhrmann, Martin, Elie Toledano, Yannick Plétan, et al. "P024 ACTISAVE study: efficacy and safety of glenzocimab on top of thrombolysis and mechanical thrombectomy." In 16th Congress of the European Society of Minimally Invasive Neurological Therapy (ESMINT) 2024. BMJ Publishing Group Ltd., 2024. http://dx.doi.org/10.1136/jnis-2024-esmint.61.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Glenzocimab' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography